Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.
Metastatic castration-resistant prostate cancer (mCRPC) has limited treatment options and a poor prognosis. Recently, PSMA-targeted alpha particle therapy agents using Actinium-225 (225Ac) have shown promising results for prostate cancer treatment, but a …